The Role of Gamma Amino Butyric Acid in Cisplatin-induced Nephrotoxicity in Streptozotocin-induced Diabetic Rats

Nasiri, Masoomeh; Soltani, Nepton; Mazaheri, Safoora; Maleki, Maryam; Talebi, Ardeshir; Gharibi, Fatemah; Nematbakhsh, Mehdi

The Role of Gamma Amino Butyric Acid in Cisplatin-induced Nephrotoxicity in Streptozotocin-induced Diabetic Rats

Document Type : Original Article

Authors

¹ Water and Electrolytes Research Center, Isfahan University of Medical Sciences, Isfahan; Department of Physiology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

² Molecular Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran

³ Water and Electrolytes Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

⁴ Department of Clinical Pathology, Faculty of Medicine, Isfahan University of Medical Science, Isfahan, Iran

⁵ Water and Electrolytes Research Center, Isfahan University of Medical Sciences, Isfahan; Department of Physiology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan; Isfahan MN Institute of Basic and Applied Sciences Research, Isfahan, Iran

Abstract

Background: Diabetes mellitus can change the risk of developing cancer. Cisplatin (CP) is a common antineoplastic drug. The major side effect of CP is nephrotoxicity. Gamma amino butyric acid (GABA) is an antioxidant agent that may have a protective role against CP-induced nephrotoxicity. The aim of the present study was to investigate the role of GABA in CP-induced nephrotoxicity in hyperglycemic male and female rats. Materials and Methods: Sixty male and female Wistar diabetic rats were used in ten experimental groups. GABA alone groups received GABA (50 μmol/kg/d i.p.) for 12 days. CP alone groups received CP (2.5 mg/kg/d i.p.) for 6 days. Other groups received GABA in the form of therapy (T) + CP, prophylaxis (P) + CP, and prophylaxis-treatment (PT) + CP. Finally, blood samples were obtained, and animals were killed for kidney tissue investigation. Results: In female rats, the serum levels of creatinine (Cr) did not change by GABA rather than CP and also there were no significant changes in blood urea nitrogen to creatinine ratio (BUN/Cr). In male rats, plasma Cr level increased by GABA (P) and (T). Body weight loss was significantly different among groups (P < 0.05). BUN/Cr ratio significantly increased in CP and GABA (PT) + CP groups. In two genders, plasma Cr level significantly decreased in CP groups (P < 0.05). The kidney levels of malondialdehyde enhanced significantly in CP groups. Conclusion: Hyperglycemia has protective effect against CP-induced nephrotoxicity. GABA did not change this effect in female, but in male in the form of PT, GABA maintained it.

Keywords

References

1.	Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al. Diabetes and cancer: A consensus report. CA Cancer J Clin 2010;60:207-21.
2.	Volkers N. Diabetes and cancer: Scientists search for a possible link. J Natl Cancer Inst 2000;92:192-4.
3.	Arany I, Sa firstein RL, editors. Cisplatin Nephrotoxicity. Seminars in Nephrology. USA Elsevier; 2003.
4.	Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of Cisplatin nephrotoxicity. Toxins (Basel) 2010;2:2490-518.
5.	Ali BH, Al Moundhri MS. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: A review of some recent research. Food Chem Toxicol 2006;44:1173-83.
6.	Ajith TA, Usha S, Nivitha V. Ascorbic acid and alpha-tocopherol protect anticancer drug cisplatin induced nephrotoxicity in mice: A comparative study. Clin Chim Acta 2007;375:82-6.
7.	Naziroglu M, Karaoglu A, Aksoy AO. Selenium and high dose vitamin E administration protects cisplatin-induced oxidative damage to renal, liver and lens tissues in rats. Toxicology 2004;195:221-30.
8.	Mohamed HE, El-Swefy SE, Mohamed RH, Ghanim AM. Effect of erythropoietin therapy on the progression of cisplatin induced renal injury in rats. Exp Toxicol Pathol 2013;65:197-203.
9.	Soltani N, Nematbakhsh M, Eshraghi-Jazi F, Talebi A, Ashrafi F. Effect of oral administration of magnesium on cisplatin-induced nephrotoxicity in normal and streptozocin-induced diabetic rats. Nephrourol Mon 2013;5:884-90.
10.	Scott LA, Madan E, Valentovic MA. Attenuation of cisplatin nephrotoxicity by streptozotocin-induced diabetes. Fundam Appl Toxicol 1989;12:530-9.
11.	Kim HY, Yokozawa T, Nakagawa T, Sasaki S. Protective effect of gamma-aminobutyric acid against glycerol-induced acute renal failure in rats. Food Chem Toxicol 2004;42:2009-14.
12.	Shi Y, Kanaani J, Menard-Rose V, Ma YH, Chang PY, Hanahan D, et al. Increased expression of GAD65 and GABA in pancreatic beta-cells impairs first-phase insulin secretion. Am J Physiol Endocrinol Metab 2000;279:E684-94.
13.	Reetz A, Solimena M, Matteoli M, Folli F, Takei K, De Camilli P. GABA and pancreatic beta-cells: Colocalization of glutamic acid decarboxylase (GAD) and GABA with synaptic-like microvesicles suggests their role in GABA storage and secretion. EMBO J 1991;10:1275-84.
14.	Sasaki S, Yokozawa T, Cho EJ, Oowada S, Kim M. Protective role of gamma-aminobutyric acid against chronic renal failure in rats. J Pharm Pharmacol 2006;58:1515-25.
15.	Kobuchi S, Tanaka R, Shintani T, Suzuki R, Tsutsui H, Ohkita M, et al. Mechanisms underlying the renoprotective effect of GABA against ischaemia/reperfusion-induced renal injury in rats. Clin Exp Pharmacol Physiol 2015;42:278-86.
16.	Kobuchi S, Shintani T, Sugiura T, Tanaka R, Suzuki R, Tsutsui H, et al. Renoprotective effects of gamma-aminobutyric acid on ischemia/reperfusion-induced renal injury in rats. Eur J Pharmacol 2009;623:113-8.
17.	Kamran M, Bahrami A, Soltani N, Keshavarz M, Farsi L. GABA-induced vasorelaxation mediated by nitric oxide and GABAA receptor in non diabetic and streptozotocin-induced diabetic rat vessels. Gen Physiol Biophys 2013;32:101-6.
18.	Ali BH, Al-Salam S, Al Za'abi M, Al Balushi KA, AlMahruqi AS, Beegam S, et al. Renoprotective effects of gamma-aminobutyric acid on cisplatin-induced acute renal injury in rats. Basic Clin Pharmacol Toxicol 2015;116:62-8.
19.	Soltani N, Qiu H, Aleksic M, Glinka Y, Zhao F, Liu R, et al. GABA exerts protective and regenerative effects on islet beta cells and reverses diabetes. Proc Natl Acad Sci U S A 2011;108:11692-7.
20.	Soltani N, Keshavarz M, Wang Q. Treatment effect of GABA on type one diabetic complication in NOD mice. Physiology and pharmacology Journal 2009;. 13(3):288-296
21.	Nematbakhsh M, Talebi A, Nasri H, Safari T, Dolatkhah S, Ashrafi F, et al. Some evidence for sex-based differences in cisplatin-induced nephrotoxicity in rats. Med Sci Technol 2012;53:RA29-32.
22.	Eshraghi-Jazi F, Nematbakhsh M, Nasri H, Talebi A, Haghighi M, Pezeshki Z, et al. The protective role of endogenous nitric oxide donor (L-arginine) in cisplatin-induced nephrotoxicity: Gender related differences in rat model. J Res Med Sci 2011;16:1389-96.
23.	Haghighi M, Nematbakhsh M, Talebi A, Nasri H, Ashrafi F, Roshanaei K, et al. The role of angiotensin II receptor 1 (AT1) blockade in cisplatin-induced nephrotoxicity in rats: Gender-related differences. Ren Fail 2012;34:1046-51.
24.	Sung MJ, Kim DH, Jung YJ, Kang KP, Lee AS, Lee S, et al. Genistein protects the kidney from cisplatin-induced injury. Kidney Int 2008;74:1538-47.
25.	Ramesh G, Reeves WB. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 2002;110:835-42.
26.	Grover B, Buckley D, Buckley AR, Cacini W. Reduced expression of organic cation transporters rOCT1 and rOCT2 in experimental diabetes. J Pharmacol Exp Ther 2004;308:949-56.
27.	Sarangarajan R, Cacini W. Early onset of cisplatin-induced nephrotoxicity in streptozotocin-diabetic rats treated with insulin. Basic Clin Pharmacol Toxicol 2004;95:66-71.
28.	Valentovic MA, Scott LA, Madan E, Yokel RA. Renal accumulation and urinary excretion of cisplatin in diabetic rats. Toxicology 1991;70:151-62.
29.	Kim J, Kil IS, Seok YM, Yang ES, Kim DK, Lim DG, et al. Orchiectomy attenuates post-ischemic oxidative stress and ischemia/reperfusion injury in mice. A role for manganese superoxide dismutase. J Biol Chem 2006;281:20349-56.
30.	Vafapour M, Nematbakhsh M, Monajemi R, Mazaheri S, Talebi A, Talebi N, et al. Effect of G-aminobutyric acid on kidney injury induced by renal ischemia-reperfusion in male and female rats: Gender-related difference. Adv Biomed Res 2015;4:158. [PUBMED] [Full text]
31.	Uchino S, Bellomo R, Goldsmith D. The meaning of the blood urea nitrogen/creatinine ratio in acute kidney injury. Clin Kidney J 2012;5:187-91.
32.	Asna N, Lewy H, Ashkenazi IE, Deutsch V, Peretz H, Inbar M, et al. Time dependent protection of amifostine from renal and hematopoietic cisplatin induced toxicity. Life Sci 2005;76:1825-34.
33.	Ohno T, Kato S, Wakatsuki M, Noda SE, Murakami C, Nakamura M, et al. Incidence and temporal pattern of anorexia, diarrhea, weight loss, and leukopenia in patients with cervical cancer treated with concurrent radiation therapy and weekly cisplatin: Comparison with radiation therapy alone. Gynecol Oncol 2006;103:94-9.
34.	Zafar M, Naqvi SN. Effects of STZ-induced diabetes on the relative weights of kidney, liver and pancreas in albino rats: A comparative study. Int J Morphol 2010;28:135-42.
35.	Vador N, Jagtap AG, Damle A. Vulnerability of gastric mucosa in diabetic rats, its pathogenesis and amelioration by cuminum cyminum. Indian J Pharm Sci 2012;74:387-96. [PUBMED] [Full text]
36.	Piyachaturawat P, Poprasit J, Glinsukon T, Wanichanon C. Gastric mucosal lesions in streptozotocin-diabetic rats. Cell Biol Int Rep 1988;12:53-63.
37.	Jones JM, Lawson ML, Daneman D, Olmsted MP, Rodin G. Eating disorders in adolescent females with and without type 1 diabetes: Cross sectional study. BMJ 2000;320:1563-6.
38.	Delgado TC. Glutamate and GABA in appetite regulation. Front Endocrinol (Lausanne) 2013;4:103.
39.	Nematbakhsh M, Ashrafi F, Nasri H, Talebi A, Pezeshki Z, Eshraghi F, et al. A model for prediction of cisplatin induced nephrotoxicity by kidney weight in experimental rats. J Res Med Sci 2013;18:370.
40.	Nakagawa T, Yokozawa T, Kim HJ, Shibahara N. Protective effects of gamma-aminobutyric acid in rats with streptozotocin-induced diabetes. J Nutr Sci Vitaminol (Tokyo) 2005;51:278-82.
41.	Jamil F, Behnam RM, Mahdavi SN, Dehghani H. Study of the effects of hyperglycemia and insulin therapy on uterus histology and estrous cycle in Wistar rat. J of Cell and Tissue 2013; 4(2): 149-157.
42.	Jilanchi S, Nematbakhsh M, Bahadorani M, Talebi A, Eshraghi-Jazi F, Mansouri A, et al. Vitamin e is a nephroprotectant agent in male but not in female in a model of Cisplatin-induced nephrotoxicity. ISRN Nephrol 2013;2013:280395.
43.	Harima Y, Harima K, Hasegawa T, Shikata N, Tanaka Y. Histopathological changes in rabbit uterus carcinoma after transcatheter arterial embolization using cisplatin. Cancer Chemother Pharmacol 1996;38:317-22.
44.	Takeshima K, Yamatsu A, Yamashita Y, Watabe K, Horie N, Masuda K, et al. Subchronic toxicity evaluation of γ-aminobutyric acid (GABA) in rats. Food Chem Toxicol 2014;68:128-34.
45.	Nielsen F, Mikkelsen BB, Nielsen JB, Andersen HR, Grandjean P. Plasma malondialdehyde as biomarker for oxidative stress: Reference interval and effects of life-style factors. Clin Chem 1997;43:1209-14.
46.	Antunes LM, Darin JD, Bianchi MD. Protective effects of Vitamin C against cisplatin-induced nephrotoxicity and lipid peroxidation in adult rats: A dose-dependent study. Pharmacol Res 2000;41:405-11.
47.	O'Gorman RL, Michels L, Edden RA, Murdoch JB, Martin E.In vivo detection of GABA and glutamate with MEGA-PRESS: Reproducibility and gender effects. J Magn Reson Imaging 2011;33:1262-7.
48.	Kurata H, Takaoka M, Kubo Y, Katayama T, Tsutsui H, Takayama J, et al. Protective effect of nitric oxide on ischemia/reperfusion-induced renal injury and endothelin-1 overproduction. Eur J Pharmacol 2005;517:232-9.
49.	Burger D, Lei M, Geoghegan-Morphet N, Lu X, Xenocostas A, Feng Q. Erythropoietin protects cardiomyocytes from apoptosis via up-regulation of endothelial nitric oxide synthase. Cardiovasc Res 2006;72:51-9.
50.	Archer S. Measurement of nitric oxide in biological models. FASEB J 1993;7:349-60.
51.	Nematbakhsh M, Sorooshzadeh SM, Pezeshki Z, Talebi A, Ashrafi F. Gender difference in the serum levels of total nitric oxide metabolites, nitrite, and nitrate in cisplatin-induced nephrotoxicity in rats. J Isfahan Med Sch 2013;30:214.
52.	Zahmatkesh M, Kadkhodaee M, Arab HA, Ahadi A. Amelioration of rat renal ischemia/reperfusion injury by L-Nil. Physiol Pharmacol 2006;10:63-9.
53.	Peresleni T, Noiri E, Bahou WF, Goligorsky MS. Antisense oligodeoxynucleotides to inducible NO synthase rescue epithelial cells from oxidative stress injury. Am J Physiol 1996;270(6 Pt 2):F971-7.
54.	Pezeshki Z, Nematbakhsh M, Mazaheri S, Eshraghi-Jazi F, Talebi A, Nasri H, et al. Estrogen abolishes protective effect of erythropoietin against cisplatin-Induced nephrotoxicity in ovariectomized rats. ISRN Oncol 2012;2012:890310.

Advanced Biomedical Research